Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML

2020 Year in Review - AML - Leukemia

The phase 2 expansion and phase 1b of the Beat AML Master Trial (phase 2/1b substudy) assessed the efficacy of enasidenib (ENA), a selective inhibitor of isocitrate dehydrogenase (IDH2), monotherapy (ENAm) in patients aged ≥60 years with newly diagnosed IDH2mut acute myeloid leukemia (AML), and subsequent response-driven addition of azacitidine (AZA) treatment.

This study began with a 3-outcome, 2-stage phase 2 design that enrolled patients for up to 5 cycles of ENAm. Patients were transferred to phase 1b, in which they received ENA + AZA if they achieved complete response (CR) or CR with incomplete hematologic recovery (CRi) following 5 cycles of ENAm, or exhibited disease progression or intolerance at any time. Patients were eligible for this study if they had newly diagnosed IDH2mut AML; were aged ≥60 years; and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received ENAm 100 mg daily in continuous 28-day cycles in phase 2 and ENA + AZA (75 mg/m2 on days 1-7 every 28 days) in phase 1b. The 2017 European LeukemiaNet AML criteria were used to assess response. The primary end point was CR/CRi rate.

At data cutoff on June 18, 2020, 60 patients were enrolled, had received ENAm, and were evaluable for the primary end point. The median age was 75 years (range, 60-89 years), and approximately half (52%) of patients were female. Median time receiving ENAm was 4.7 months. Twelve patients were still receiving ENAm treatment at data cutoff. The most common reasons for treatment discontinuation were treatment failure (no response to treatment, 38%), disease progression (loss of response to treatment, 12%) and adverse events (AEs; 10%). Five (8%) patients received an allogeneic stem-cell transplant (allo-SCT). A total of 28 patients achieved CR/CRi (47%; adjusted 95% confidence interval [CI], 34-60). Responses were higher in patients with IDH2R140 mutation (55%) than in those with IDH2R172 mutation (25%; P = .04). The median overall survival (mOS) was 24.4 months (95% CI, 10.6-not evaluable) after a median follow-up of 14.6 months. The median duration of response (DOR) was not reached, with a landmark 12-month DOR rate estimate of 57% (95% CI, 34-75). Overall, 20 treatment-related serious adverse events (SAEs) occurred in 15 patients, the most common being differentiation syndrome (21.7%). Two patients had tumor lysis syndrome. The most common AEs (in ≥20% of patients) of any grade were nausea (56.7%), anemia (51.7%), and low potassium (48.3%).

A total of 17 patients had inadequate response to ENAm and moved to phase 1b, in which they received ENA + AZA. Including ENAm, for these patients, the median time on treatment was 6.2 months. Median time on treatment after starting ENA + AZA was 2.1 months. The most common reasons for treatment discontinuation were treatment failure (29%), disease progression (12%), allo-SCT, death, and AEs (each 12%). The CR/CRi rate was 41% (exact 95% CI, 18-67). The mOS was 8.9 months after a median follow-up of 12.7 months from start of the ENA + AZA combination. Four ENA-related SAEs occurred in 3 patients, the most common being differentiation syndrome (16.7%). One dose-limiting toxicity (grade 3 nausea) related to both treatments was observed. The most common AEs (≥20% of patients) of any grade were anemia (43.8%), low albumin (37.5%), and vomiting (37.5%).

In conclusion, treatment with ENA among newly diagnosed patients with IDH2mut AML was associated with low early death rate and high CR/CRi rate and yielded durable remissions. Differentiation syndrome was the most common unique toxicity. A subset of patients who did not achieve CR/CRi with ENAm achieved CR/CRi with the addition of AZA. Monotherapy with ENA followed by the addition of AZA in patients with suboptimal response resulted in an mOS of more than 2 years.

Reference

Stein EM, Huang Y, Borate U, et al. Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. Presented at: 62nd American Society of Hematology Annual Meeting & Exposition, December 5-8, 2020. Abstract 635.

Related Items
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Effect of Concomitant Azole Antifungals on Duration of Myelosuppression in Newly Diagnosed Patients with AML Receiving Venetoclax in Combination with Cladribine and Low-Dose Cytarabine
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Leukemia
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia, Adverse Events
Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer
Lisa R. Garavaglia, PharmD , Frank Casey, MD, Lesley Cottrell, PhD, Claudiu Faraon-Pogaceanu, MD, Stephan Paul, MD, Melvin Lee Wright, DO
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Original Article, Pediatric Cancer, Leukemia, Lymphoma
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study
Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Leukemia, Oncology Pharmacy Programs
Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia
Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Case Reports, Acute Lymphoblastic Leukemia, Leukemia, Adverse Events
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
Copyright © The Lynx Group, LLC. All rights reserved.